What Trade-Offs Do Consumers And Physicians Make In Choosing Rx Drug Treatments?
Executive Summary
US FDA study is to examine the relative importance of product information, such as efficacy, risk and patient preference claims, in the treatment preferences of consumers and physicians.
You may also be interested in...
Do Patients Understand The Term ‘Median’ In Advertising? US FDA Aims To Find Out
In first Rx advertising research project of 2023, FDA will survey consumers on how they interpret quantitative claims in DTC ads. Lilly questions design of another study examining relative importance of product information, citing FDA comments at tanezumab advisory committee.
Pitching Drugs To Physicians: Disclosing Limitations Of Clinical Data May Be Beneficial
US FDA study finds that sales aids for oncology drugs that disclose a study’s data limitations and clinical uncertainty can lead to more appropriate assessments of the data by physicians but does not affect their overall perceptions of a drug’s benefits.
Rx Drug Promotion: Inclusion Of Extensive Risk Info In Twitter, Google Ads Has Potential Drawback
US FDA study of character-space-limited prescription drug communications finds consumers may be less likely to click on a link for more risk information if the promo already has substantial details.